Efficacy and safety of bulevirtide monotherapy given at 2-mg or 10-mg dose level once daily for treatment of chronic hepatitis delta: Week 48 primary endpoint results from a Phase 3 randomized, multicenter, parallel design study - Wedemeyer, H.; Deterding, K.; Aleman, S.; Brunetto, M.; Blank, A.; Andreone, P.; Bogomolov, P.; Chulanov, V.; Mamonova, N.; Geyvandova, N.; Morozov, V.; Sagalova, O.; Stepanova, T.; Manuilov, D.; Suri, V.; An, Q.; Flaherty, J.; Osinusi, A.; Schulze zur Wiesch, J.; Cornberg, M.; Zeuzem, S.; Lampertico, P. (Zeitschrift für Gastroenterologie, 2023)